3 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
Follow bezlotoxumab: new trials by email Literature Review of bezlotoxumab trials Research Report on bezlotoxumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001) Bezlotoxumab, Placebo, Antibacterial drug treatment (ABD) - Clostridium Difficile Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 148 | 2018-03-27 | 2023-07-27 |
| A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002) MK-6072, MK-3415A, Placebo - Clostridium Difficile Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1203 | 2012-02-01 | 2018-09-05 |
| A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001) MK-3415, MK-6072, MK-3415A - Clostridium Difficile Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1452 | 2011-10-10 | 2018-09-05 |
Argentina (1) · Brazil (1) · Colombia (1) · Czechia (1) · Germany (1) · Hungary (1) · Malaysia (1) · Mexico (1) · Norway (1) · Poland (1) · Portugal (1) · Romania (1) · South Africa (1) · Spain (1) · Sweden (1)
PMID 28121498, PMID 29538686, PMID 29788418, PMID 30060024, PMID 30227108, PMID 30455246, PMID 30460321, PMID 31411386, PMID 31628838, PMID 32099847, PMID 32376702, PMID 32504314, PMID 36661328, PMID 27316794, PMID 31846705, PMID 31883370, PMID 32101275, PMID 36906440, PMID 37389891
2017 (1)